These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 2832448)

  • 1. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
    Yasuda T; Gold HK; Fallon JT; Leinbach RC; Guerrero JL; Scudder LE; Kanke M; Shealy D; Ross MJ; Collen D; Coller BS
    J Clin Invest; 1988 Apr; 81(4):1284-91. PubMed ID: 2832448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
    Yasuda T; Gold HK; Leinbach RC; Saito T; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
    J Am Coll Cardiol; 1990 Dec; 16(7):1728-35. PubMed ID: 2123910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.
    Gold HK; Coller BS; Yasuda T; Saito T; Fallon JT; Guerrero JL; Leinbach RC; Ziskind AA; Collen D
    Circulation; 1988 Mar; 77(3):670-7. PubMed ID: 3124974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
    Mickelson JK; Simpson PJ; Cronin M; Homeister JW; Laywell E; Kitzen J; Lucchesi BR
    Circulation; 1990 Feb; 81(2):617-27. PubMed ID: 2105175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.
    Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):194-202. PubMed ID: 7511747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T; Gold HK; Yaoita H; Leinbach RC; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
    J Am Coll Cardiol; 1990 Sep; 16(3):714-22. PubMed ID: 2117620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons.
    Kohmura C; Gold HK; Yasuda T; Holt R; Nedelman MA; Guerrero JL; Weisman HF; Collen D
    Arterioscler Thromb; 1993 Dec; 13(12):1837-42. PubMed ID: 8241105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
    Spriggs D; Gold HK; Hashimoto Y; Van Houtte E; Vermylen J; Collen D
    Thromb Haemost; 1989 Feb; 61(1):93-6. PubMed ID: 2501892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart.
    Mickelson JK; Simpson PJ; Lucchesi BR
    J Mol Cell Cardiol; 1989 Apr; 21(4):393-405. PubMed ID: 2746660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP; Tschopp TB; Kuhn H; Steiner B; Hadváry P
    J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T; Gold HK; Leinbach RC; Yaoita H; Fallon JT; Guerrero L; Napier MA; Bunting S; Collen D
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous administration of the glycoprotein IIb-IIIa receptor antagonist 7E3 induces reperfusion of an acute thrombotic occlusion of the canine coronary artery.
    Shetler TJ; Bailey BD; Jakubowski JA; Jackson CV
    Thromb Res; 1998 Apr; 90(2):95-100. PubMed ID: 9684763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.
    Fitzgerald DJ; Wright F; FitzGerald GA
    Circ Res; 1989 Jul; 65(1):83-94. PubMed ID: 2500270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody [7E3 F(ab')2] prevents arterial but not venous rethrombosis.
    Sudo Y; Kilgore KS; Lucchesi BR
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):241-50. PubMed ID: 7475049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ; Prager NA; Sobel BE; Abendschein DR
    Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
    Fitzgerald DJ; Hanson M; FitzGerald GA
    J Clin Invest; 1991 Nov; 88(5):1589-95. PubMed ID: 1939647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty.
    Bates ER; McGillem MJ; Mickelson JK; Pitt B; Mancini GB
    Circulation; 1991 Dec; 84(6):2463-9. PubMed ID: 1659954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of the effects of a single bolus injection of F(ab')2 fragments of the antiplatelet GPIIb/IIIa antibody 7E3 on arterial eversion graft occlusion, platelet aggregation, and bleeding time in dogs.
    Kiss RG; Lu HR; Roskams T; Jang IK; Plow EF; Gold HK; Collen D
    Arterioscler Thromb; 1994 Mar; 14(3):367-74. PubMed ID: 8123640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.